Amgen (AMGN) Stock

Instead of just focusing on Wall Street's predictions for Amgen's (AMGN) earnings, let's explore some important metrics to better understand how the company might perform in the quarter that ends in December 2024. This will provide a clearer picture of its potential success.

In the fourth quarter, increasing patient numbers, new technology, and rising rates are expected to help healthcare companies. Firms such as AMGN, COR, HUM, and ARDT are likely to do better than others.

Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.

The increase in sales for AMGN's main medications, such as Prolia, Repatha, and Evenity, is likely to have been somewhat balanced out by competition from biosimilars and generics for older drugs.

On the most recent trading day, Amgen (AMGN) closed at $280.30, which is a decrease of 0.94% compared to its last closing price.

Amgen (AMGN) has the right mix of factors that could lead to a strong earnings report in the near future. Be ready for the important expectations.

Lately, users of Zacks.com have been focusing on Amgen (AMGN). This interest prompts a closer look at what the stock might offer.

Amgen (AMGN) closed at $277.88 on the most recent trading day, showing an increase of 1.62% from its previous closing price.

Amgen (AMGN) closed at $277.88 on the most recent trading day, showing an increase of 1.62% from its previous closing price.